The Low HDL On six Weeks statin therapy (LOW) study

Craigavon Area Hospital Group Trust0 个研究点开始时间: 2005年9月9日最近更新: 2013年7月15日

适应症

试验速览

暂无简介。

•1. Persisting low HDL-C (<0.9mmol/l) on a full lipid profile result (which for inpatients should have been taken <24 hours after admission).
•2. Objective diagnosis of coronary heart disease (previous biomarker proven MI, positive stress test, angiogram with at least one >50% diameter stenosis)
•3. Established for at least 6 weeks on a maintenance” dose of statin therapy (defined as Pravastatin 40mg, Simvastatin 40mg or Atorvastatin =10mg). The dose and type of statin should not be altered during the study period
•4. Absence of concurrent major systemic illness (particularly liver or renal failure, or hypo or hyperthyroidism)
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1. Previous use of Niaspan or other non-statin lipid lowering agent within the previous 12 weeks
•2. Contraindications to Niaspan therapy
•3. Participation in another medical trial within the previous 30days
•4. Failure to obtain informed consent

发起方

Craigavon Area Hospital Group Trust